Blood eosinophils as a biomarker of future COPD exacerbation risk: pooled data from 11 clinical trials.

Respir Res 2020 Sep 17;21(1):240. Epub 2020 Sep 17.

Clinical Science Centre, Institute of Ageing and Chronic Disease, University of Liverpool, Liverpool, UK.

Background: Chronic obstructive pulmonary disease (COPD) is characterised by progressive airflow limitation and chronic inflammation. Predicting exacerbations of COPD, which contribute to disease progression, is important to guide preventative treatment and improve outcomes. Blood eosinophils are a biomarker for patient responsiveness to inhaled corticosteroids (ICS); however, their effectiveness as a predictive biomarker for COPD exacerbations is unclear.

Methods: This post hoc analysis pooled data from 11 Boehringer Ingelheim-sponsored Phase III and IV randomised COPD studies with similar methodologies. Exacerbation data were collected from these studies, excluding patients from the ICS withdrawal arm of the WISDOM® study. Patients were grouped according to their baseline blood eosinophil count, baseline ICS use and number of exacerbations in the year prior to each study.

Results: Exacerbation rate data and baseline eosinophil count were available for 22,125 patients; 45.6% presented with a baseline blood eosinophil count of ≤ 150 cells/μL, 34.3% with 150-300 cells/μL and 20.1% with > 300 cells/μL. The lowest exacerbation rates were observed in patients with ≤ 150 cells/μL, with small increases in exacerbation rate observed with increasing eosinophil count. When stratified by exacerbation history, the annual rate of exacerbations for patients with 0 exacerbations in the previous year increased in line with increasing eosinophil counts (0.38 for ≤ 150 cells/μL, 0.39 for 150-300 cells/μL and 0.44 for > 300 cells/μL respectively). A similar trend was identified for patients with one exacerbation in the previous year, 0.62, 0.66 and 0.67 respectively. For patients with ≥ 2 exacerbations, exacerbation rates fluctuated between 1.02 (≤ 150 cells/μL) to 1.10 (150-300 cells/μL) and 1.07 (> 300 cells/μL). Higher exacerbation rates were noted in patients treated with ICS at baseline (range 0.75 to 0.82 with increasing eosinophil count) compared with patients not on ICS (range 0.45 to 0.49).

Conclusion: We found no clinically important relationship between baseline blood eosinophil count and exacerbation rate. Hence, the current analysis does not support the use of blood eosinophils to predict exacerbation risk; however, previous exacerbation history was found to be a more reliable predictor of future exacerbations.

Trial Registration: ClinicalTrials.gov Identifiers: NCT00168844 , NCT00168831 , NCT00387088 , NCT00782210 , NCT00782509 , NCT00793624 , NCT00796653 , NCT01431274 , NCT01431287 , NCT02296138 and NCT00975195 .

Download full-text PDF

Source
http://dx.doi.org/10.1186/s12931-020-01482-1DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7499955PMC
September 2020

Publication Analysis

Top Keywords

eosinophil count
24
≤ 150 cells/μl
16
exacerbation rate
12
exacerbation
12
blood eosinophil
12
150-300 cells/μl
12
blood eosinophils
12
increasing eosinophil
12
exacerbation rates
12
> 300 cells/μl
12
baseline blood
12
cells/μl
10
patients
9
patients ics
8
exacerbation history
8
previous year
8
exacerbation risk
8
eosinophils biomarker
8
pooled data
8
eosinophil
7

Similar Publications

Blood eosinophil count and exacerbations in severe chronic obstructive pulmonary disease after withdrawal of inhaled corticosteroids: a post-hoc analysis of the WISDOM trial.

Lancet Respir Med 2016 05 7;4(5):390-8. Epub 2016 Apr 7.

Institute of Ageing and Chronic Disease, Aintree University Hospital, Liverpool, UK.

Background: Blood eosinophil counts might predict response to inhaled corticosteroids (ICS) in patients with chronic obstructive pulmonary disease (COPD) and a history of exacerbations. We used data from the WISDOM trial to assess whether patients with COPD with higher blood eosinophil counts would be more likely to have exacerbations if ICS treatment was withdrawn.

Methods: WISDOM was a 12-month, randomised, parallel-group trial in which patients received 18 μg tiotropium, 100 μg salmeterol, and 1000 μg fluticasone propionate daily for 6 weeks and were then randomly assigned (1:1) electronically to receive either continued or reduced ICS over 12 weeks. Read More

View Article and Full-Text PDF
May 2016

Blood eosinophil count, a marker of inhaled corticosteroid effectiveness in preventing COPD exacerbations in post-hoc RCT and observational studies: systematic review and meta-analysis.

Respir Res 2020 Jan 3;21(1). Epub 2020 Jan 3.

Department of Public Health and Primary Care, School of Population Health & Environmental Sciences, King's College London, 3rd floor Addison House, Guys Campus, London, SE1 1UL, UK.

Background: Blood eosinophil count has been proposed as a predictor of response to inhaled corticosteroid (ICS) in the prevention of acute exacerbations of COPD. An optimal threshold of blood eosinophil count for prescribing ICS has not been agreed. Doubt has been cast on the role by observational studies. Read More

View Article and Full-Text PDF
January 2020

Blood eosinophils: a biomarker of COPD exacerbation reduction with inhaled corticosteroids.

Int J Chron Obstruct Pulmon Dis 2018;13:3669-3676. Epub 2018 Nov 6.

Chiesi Farmaceutici SpA, Parma, Italy.

Background: Growing evidence suggests that blood eosinophil count is associated with patient responsiveness to inhaled corticosteroids (ICS). We performed post hoc predictive modeling on data from the FORWARD study and two replicate studies by Dransfield, to evaluate the relationships between baseline eosinophil count and the effect of ICS on exacerbations and lung function in patients with COPD.

Methods: The studies assessed ICS/long-acting β agonist (LABA) combinations vs LABA alone. Read More

View Article and Full-Text PDF
April 2019

Tiotropium/Olodaterol Decreases Exacerbation Rates Compared with Tiotropium in a Range of Patients with COPD: Pooled Analysis of the TONADO/DYNAGITO Trials.

Adv Ther 2020 10 10;37(10):4266-4279. Epub 2020 Aug 10.

Clinical Science Centre, Institute of Ageing and Chronic Disease, University of Liverpool, Liverpool, UK.

Introduction: Previous studies demonstrated that tiotropium/olodaterol reduced rates of exacerbations in patients with chronic obstructive pulmonary disease (COPD). However, this should be examined in a wider population.

Methods: This post hoc analysis pooled data from TONADO 1 + 2 and DYNAGITO, three 52-week, parallel-group, randomised, double-blind, phase III trials investigating patients with moderate-to-very severe COPD, with and without previous exacerbations, who received tiotropium/olodaterol 5/5 µg or tiotropium 5 µg. Read More

View Article and Full-Text PDF
October 2020